Listar MD - Artículos por autor "Díaz-Redondo, Tamara"
Mostrando ítems 1-2 de 2
-
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso
; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ...